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Abstract
Phenethyl isothiocyanate (PEITC) is a promising cancer chemopreventive component of edible cruciferous vegetables with
in vivo efficacy against prostate cancer in experimental rodents. Cancer chemopreventive response to PEITC is characterized
by its ability to inhibit multiple oncogenic signaling pathways, including nuclear factor-kB, Akt, and androgen receptor. The
present study demonstrates, for the first time, that PEITC treatment activates Notch signaling in malignant as well as normal
human prostate cells. Exposure of human prostate cancer cells (LNCaP, PC-3, and DU145) and a normal human prostate
epithelial cell line (PrEC) to PEITC resulted in cleavage (active form) of Notch1 and Notch2, and increased transcriptional
activity of Notch. In PC-3 and LNCaP cells, PEITC treatment caused induction of Notch ligands Jagged1 and Jagged2 (PC-3),
overexpression of c-secretase complex components Presenilin1 and Nicastrin (PC-3), nuclear enrichment of cleaved Notch2,
and/or up-regulation of Notch1, Notch2, Jagged1, and/or Jagged2 mRNA. PEITC-induced apoptosis in LNCaP and PC-3 cells
was significantly attenuated by RNA interference of Notch2, but not by pharmacological inhibition of Notch1. Inhibition of
PC-3 and LNCaP cell migration resulting from PEITC exposure was significantly augmented by knockdown of Notch2 protein
as well as pharmacological inhibition of Notch1 activation. Nuclear expression of cleaved Notch2 protein was significantly
higher in PC-3 xenografts from PEITC-treated mice and dorsolateral prostates from PEITC-fed TRAMP mice compared with
respective control. Because Notch signaling is implicated in epithelial-mesenchymal transition and metastasis, the present
study suggests that anti-metastatic effect of PEITC may be augmented by a combination regimen involving a Notch
inhibitor.
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Introduction
Practical and safe modalities for chemoprevention of prostate
cancer are clinically attractive because of high mortality
associated with this malignancy in American men [1]. Plant
products, including constituents of fruits and vegetables, continue
to attract attention for the discovery of novel cancer chemopre-
ventive agents [2]. Phenethyl isothiocyanate (PEITC) is one such
promising cancer chemopreventive agent abundant in edible
cruciferous vegetables such as watercress [3]. Evidence for
protective effect of cruciferous vegetables and their components,
including PEITC, against prostate cancer derives from popula-
tion-based observational studies as well as laboratory investiga-
tions [3–9]. For example, a population-based case-control study
suggested an inverse association between intake of cruciferous
vegetables and the risk of prostate cancer [4]. In vivo chemopre-
ventive efficacy of PEITC against prostate cancer has now been
established in a transgenic mouse model (Transgenic Adenocar-
cinoma of Mouse Prostate model; hereafter abbreviated as
TRAMP) [5,6]. Feeding of 3 mmol PEITC/g diet significantly
decreased incidence as well as burden (affected area) of poorly-
differentiated cancer in the dorsolateral prostate of TRAMP mice
[6]. Cancer chemopreventive response to PEITC is not restricted
to the prostate cancer as inhibition of chemical carcinogenesis or
suppression of spontaneous cancer development of other sites
(e.g., lung, colon, and esophagus) by this dietary component has
also been documented [7–9]. Furthermore, growth of subcuta-
neous prostate cancer xenografts in athymic mice was signifi-
cantly retarded by administration of PEITC or its N-acetylcys-
teine conjugate [10–12]. Notably, oral PEITC administration
augmented proapoptotic response to docetaxel in vivo in prostate
cancer xenografts [13].
Safety, bioavailability, selectivity towards cancer cells, and
ability to target multiple oncogenic pathways are desirable
attributes of a clinically useful cancer chemopreventive agent.
Research thus far indicates that PEITC meets all these criteria.
Firstly, PEITC is well-tolerated by experimental rodents [6–9].
Secondly, pharmacokinetic determinations indicate excellent
bioavailability of PEITC [14,15]. Thirdly, PEITC also shows
selectivity towards cancer cells in causing apoptosis and autophagy
[11,16,17]. Finally, PEITC is capable of suppressing multiple
oncogenic signaling pathways that are hyperactive in human
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Akt [20], signal transducer and activator of transcription 3
(STAT3) [21], and androgen receptor [22].
The present study extends these observations [19–22] and
examines the effect of PEITC treatment on activation of Notch1
and Notch2, which belong to a family of transmembrane receptors
implicated in prostate cancer development and metastasis [23],
using cultured human prostate cancer cells (LNCaP, PC-3,
LNCaP2C4-2, and DU145), a normal human prostate epithelial
cell line (PrEC), PC-3 xenografts from control and PEITC-treated
mice [13,16], and dorsolateral prostate from control and PEITC-
fed TRAMP mice [6].
Results
PEITC treatment increases levels of cleaved Notch1 and
Notch2 in prostate cancer cells
Ligand-dependent activation of Notch is complex requiring
cleavage by c-secretase complex [23,24]. Notch receptors are
activated upon binding of their adjoining ligands (e.g., Jagged1 and
Jagged2), which is thought to induce a conformational change
within the Notch receptor resulting in exposure of an S2 cleavage
site for tumor necrosis factor-a converting enzyme [23,24].
Subsequently, Notch receptors undergo another cleavage mediat-
ed by the c-secretase complex at a site located within the Notch
transmembrane domain [24]. Net outcome of this cleavage is the
release of the Notch intracellular domain into the cytoplasm,
which then translocates to the nucleus to regulate target gene
expression [23,24]. Level of cleaved Notch1 protein was increased
upon treatment with PEITC in both LNCaP (Fig. 1A) and PC-3
cells (Fig. 1B) albeit with different kinetics and intensity. To the
contrary, PEITC treatment caused a robust and sustained increase
in the level of cleaved Notch2 protein in both LNCaP (Fig. 1A)
and PC-3 cell lines (Fig. 1B) especially at the 5 mM dose. Based on
Notch2 RNA interference data shown later, the lower band in the
Notch2 western blot shown in Fig. 1B is non-specific. Effect of
PEITC treatment on Jagged1 and Jagged2 protein expression was
different between LNCaP and PC-3 cells. PEITC-treated LNCaP
cell line generally exhibited a decrease in the levels of Jagged1 and
Jagged2 proteins (Fig. 1A). In sharp contrast to LNCaP, transient
(Jagged1) or sustained (Jagged2) induction of Jagged protein
expression was clearly visible in PEITC-treated PC-3 cells (Fig. 1B).
Differential responses were also discernible concerning effect of
PEITC treatment on Presenilin1 and Nicastrin proteins between
LNCaP and PC-3 cells especially at the 8-hour time point.
PC-3 cell line, which is androgen-independent, is relatively
more aggressive compared with androgen-responsive LNCaP cells
with respect to proliferation, in vivo growth in xenograft model, and
cell migration. We questioned if differential response of LNCaP
versus PC-3 cells to PEITC-mediated alterations in Notch signaling
components was related to androgen-independent phenotype. We
addressed this question using an androgen-independent variant of
LNCaP cells (LNCaP2C4-2). Response of LNCaP2C4-2 cells to
PEITC-mediated changes in Notch signaling proteins was
generally similar to that observed in the parental LNCaP cells
(Fig. 1C). Together, these observations indicated that while PC-3
and LNCaP cells differentially responded to PEITC-mediated
changes in Notch ligands and c-secretase complex, cleavage of
Notch1 and Notch2 proteins upon PEITC exposure was consistent
in each cell line tested. Also, transition of LNCaP cells to
androgen-independence (LNCaP2C4-2) does not have any
meaningful impact on PEITC-mediated changes in levels of
Notch signaling components.
PEITC treatment increases transcriptional activity of
Notch
We questioned whether PEITC-mediated cleavage of Notch1
and Notch2 translated into increased transcriptional activity of
Notch. As shown in Fig. 2A, treatment of LNCaP and, PC-3 cells
with 5 mM PEITC resulted in a statistically significant increase in
luciferase reporter activity of RBP-Jk (a downstream modulator of
Notch signaling) compared with dimethyl sulfoxide (DMSO)-
treated controls. We used another well-characterized castration-
resistant human prostate cancer cell line (DU145) to determine the
effect of PEITC treatment on transcriptional activity of Notch. As
can be seen in Fig. 2A, PEITC treatment increased RBP-Jk
luciferase reporter activity in DU145 cells as well. In addition,
PEITC-treated DU145 cells exhibited similar kinetics of Notch1
and Notch2 cleavage (Fig. 2B) as observed in the PC-3 cell line
(Fig. 1B).
Next, we used a normal human prostate epithelial cell line
(PrEC) to determine if PEITC-mediated activation of Notch1 and
Notch2 was unique to cancerous prostate cells. This was a worthy
research objective considering striking differences have been noted
with regards to effect of PEITC between cancerous and normal
prostate cells. For example, we have shown previously that the
PrEC cell line is significantly resistant to PEITC-mediated
inhibition of oxidative phosphorylation, reactive oxygen species
generation, and apoptosis induction compared with PC-3 and
LNCaP cells [11,17]. Furthermore, PC-3 and PrEC cells respond
differentially to PEITC-mediated changes in expression of
antioxidant defense genes [25]. Similar to prostate cancer cells
(Fig. 1), PEITC treatment resulted in increased levels of cleaved
Notch1 and Notch2 in PrEC cells especially at the 16-hour time
point at both 2.5 and 5 mM concentrations (Fig. 2B). Consistent
with results, PEITC-mediated increase in RBP-Jk luciferase
reporter activity was also observed in PrEC cells after 16-hour
treatment with 5 mM PEITC (Fig. 2A). Based on these results, we
conclude that PrEC and cancerous prostate cells (PC-3, LNCaP,
LNCaP2C4-2, and DU145) behave similarly with respect to
PEITC-mediated activation of Notch.
Effect of PEITC treatment on nuclear levels of cleaved
Notch2
Because the effect of PEITC treatment was relatively more
pronounced and sustained on Notch2 cleavage compared with
cleaved Notch1, we proceeded to determine cleaved Notch2 levels
in DMSO-treated control and PEITC-treated LNCaP and PC-3
cells. PEITC-treated LNCaP and PC-3 cells exhibited a marked
increase in the nuclear levels of cleaved Notch2 in comparison
with DMSO-treated control (Fig. 3A). These results indicated that
PEITC treatment resulted in nuclear enrichment of cleaved
Notch2 in prostate cancer cells, which is consistent with the
observed increase in transcriptional activity of Notch by PEITC
treatment (Fig. 2A).
Effect of PEITC treatment on Notch1, Notch2, Jagged1,
and Jagged2 mRNA levels
Data for the effect of PEITC treatment on mRNA levels of
Notch1, Notch2, Jagged1, and Jagged2 are shown in Fig. 3B (LNCaP)
and Fig. 3C (PC-3). Expression of Notch1 (2.5 and 5 mM PEITC)
and Jagged1 (5 mM PEITC) mRNA was increased significantly
upon 8-hour treatment of LNCaP cells with PEITC (Fig. 3B). A
similar PEITC treatment resulted in suppression of Notch2 (5 mM
PEITC) and Jagged2 (5 mM PEITC) mRNA levels in LNCaP cells
(Fig. 3B). On the other hand, PC-3 cells treated for 8 hours with
5 mM PEITC exhibited significant induction of Notch1, Notch2,
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treated control (Fig. 3C). Significant induction of Notch1, Jagged1,
and Jagged2 mRNA with 2.5 mM PEITC treatment was also
observed in PC-3 cells (Fig. 3C). Once again, these results pointed
towards cell line-specific differences in PEITC-mediated alter-
ations in expression of Notch1, Notch2, Jagged1, and Jagged2 mRNA.
RNA interference of Notch2 confers protection against
PEITC-induced apoptosis
O’Neill et al [26] have shown previously that Notch2 regulates
apoptosis in MDA-MB-231 cells. Because PEITC treatment
consistently increased the levels of cleaved Notch2 protein in each
cell line tested, it was only logical to determine if Notch2
contributed to PEITC-induced apoptosis. As shown in Fig. 4A,
protein level of cleaved Notch2 was decreased by about 40–60%
upon transient transfection of LNCaP and PC-3 cells with a
Notch2-targeted small-interfering RNA (siRNA) in comparison
with cells transfected with a control (non-specific) siRNA. PEITC-
mediated increase in levels of cleaved Notch2 protein was clearly
visible in control siRNA-transfected LNCaP and PC-3 cells, which
was nearly fully abolished by RNA interference of Notch2
(Fig. 4A). Knockdown of Notch2 protein alone did not have any
meaningful impact on histone-associated DNA fragment release
into the cytosol, which is a well-accepted method for quantitation
of apoptosis, in either cell line (Fig. 4B). On the other hand,
PEITC-induced apoptosis was relatively more pronounced in
LNCaP and PC-3 cells transfected with the control siRNA
compared with those transfected with Notch2-targeted siRNA
(Fig. 4B). These results indicated that Notch2 knockdown
conferred protection against PEITC-induced apoptosis.
We designed experiments using a pharmacological inhibitor of
c-secretase {N-[N-(3,5-difluorophenacetyl-L-alanyl)]-S-phenylgly-
cine-t-butyl ester; hereafter abbreviated as DAPT} to further test
the role of Notch in PEITC-induced apoptosis. PEITC-mediated
increase in levels of cleaved Notch1 protein, but not cleaved
Notch2, was markedly suppressed by co-treatment with 50 mM
DAPT (Fig. 4C). As expected, DAPT treatment alone decreased
levels of cleaved Notch1 and Notch2 in both LNCaP and PC-3
cells, albeit to varying extent (Fig. 4C). PEITC-induced apoptosis
was either not altered at all (PC-3 cells) or slightly increased
(LNCaP cells) by co-treatment with DAPT (Fig. 4D). Based on
these results, we conclude that activation of Notch2, but not
Notch1, contributes to PEITC-induced apoptosis at least in PC-3
cells.
RNA interference of Notch2 augments PEITC-mediated
inhibition of cell migration
Because Notch signaling is implicated in cell invasion and
epithelial-mesenchymal transition (EMT) [27,28], we designed
functional experiments to determine the consequences of Notch
activation on PEITC’s ability to inhibit LNCaP and PC-3 cell
migration. Transient transfection with Notch2-targeted siRNA
alone resulted in suppression of LNCaP (Fig. 5A) and PC-3
(Fig. 5C) cell migration compared with corresponding control
siRNA-transfected cells as determined by Boyden chamber assay.
Migration of control siRNA-transfected LNCaP (Fig. 5B) and PC-
3 cells (Fig. 5D) was also reduced significantly upon treatment with
5 mM PEITC. Furthermore, PEITC-mediated inhibition of
LNCaP (Fig. 5B) and PC-3 (Fig. 5D) cell migration was
significantly augmented by knockdown of the Notch2 protein.
Pharmacological suppression of Notch1 activation
augments PEITC-mediated inhibition of cell migration
DAPT alone caused a modest decrease in LNCaP (Fig. 6A) and
PC-3 (Fig. 6C) cell migration compared with respective DMSO-
treated control. Similar to data using Notch2 siRNA, co-treatment
with DAPT augmented PEITC-mediated inhibition of LNCaP
(Fig. 6B) and PC-3 (Fig. 6D) cell migration. These results indicated
that Notch1 and Notch2 activation by PEITC negatively impacts
its ability to inhibit prostate cancer cell migration.
Immunohistochemical analysis for the effect of PEITC on
cleaved Notch2 protein in vivo
We used archived tissues from our previously completed studies
[6,13,16] to determine in vivo relevance of the cellular findings
(Fig. 1). Because the effect of PEITC treatment was most
consistent and sustained on cleaved Notch2, the immunohisto-
chemical analysis was restricted to this protein. Representative
immunohistochemical images for cleaved Notch2 expression in
PC-3 tumor xenograft sections from control and PEITC-treated
mice are shown in Fig. 7A. In agreement with the results shown in
cultured PC-3 cells (Fig. 3A) nuclear expression of cleaved Notch2
was significantly higher in PC-3 xenografts from PEITC-treated
mice compared with control (Fig. 7A). Similarly, the nuclear level
of cleaved Notch2 protein in the dorsolateral prostate was
significantly higher in PEITC-fed TRAMP mice compared with
control (Fig. 7B).
Discussion
Precise role of Notch signaling in prostate cancer development
is still unclear, but studies have tried to resolve this issue with the
use of prostate cancer cell lines and human prostate cancer
biopsies. Down-regulation of Jagged1 has been shown to inhibit
proliferation of prostate cancer cells [29]. The same group of
investigators reported later that RNA interference of Notch1
conferred protection against prostate cancer cell migration and
invasion [30]. At the same time, overexpression of constitutively
active Notch1 has also been shown to inhibit proliferation of
LNCaP cells [31]. Because Notch signaling is quite complex
involving interplay between four receptors (Notch1-Notch4) and
five ligands [Jagged1, Jagged2, Delta-like ligands (Dll1, Dll3, and
Dll4)] [23,24] and each component of Notch signaling is not
commonly studied [29–31], it is plausible that the discrepancy
stems from compensatory changes in other components triggered
by knockdown of Notch1 or Jagged1. Nevertheless, Jagged1
expression in prostate cancer biopsies is associated with increased
metastasis and recurrence [32]. The present study reveals that
PEITC activates Notch1 and Notch2 in cancerous and normal
prostate cells. Moreover, PEITC administration causes significant
increase in nuclear levels of cleaved Notch2 in vivo in prostate
tumors from two different rodent models. We also demonstrate
Figure 1. Phenethyl isothiocyanate (PEITC) increases levels of cleaved Notch1 and cleaved Notch2 in prostate cancer cells.
Immunoblotting for cleaved Notch1, cleaved Notch2, Jagged1, Jagged2, Presenilin1, and Nicastrin using lysates from (A) LNCaP, (B) PC-3, and (C)
LNCaP2C4-2 cells after 8-, 16-, or 24-hour treatment with dimethyl sulfoxide (DMSO) or PEITC (2.5 or 5 mM). Arrow in panel B identifies cleaved
Notch2, the lower band is non-specific based on siRNA results shown in Fig. 4A. Blots were stripped and re-probed with anti-actin antibody.
Immunoblotting for each protein was done at least twice using independently prepared lysates. Numbers above band represent changes in protein
levels relative to corresponding DMSO-treated control.
doi:10.1371/journal.pone.0026615.g001
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inhibit prostate cancer cell migration. Based on these observations,
we are tempted to speculate that anti-metastatic effect of PEITC
may be augmented by a combination regimen involving a Notch
inhibitor.
LNCaP and PC-3 cells exhibit striking differences with regards
to PEITC-mediated alterations in Notch signaling components,
especially Notch ligands and c-secretase components. Two
obvious possibilities deserve attention to explain these differences
in PEITC response between androgen-responsive LNCaP cells
(wild-type p53) versus castration-resistant and p53-null PC-3 cells.
One such possibility relates to difference in status of p53 between
LNCaP and PC-3 cells as Notch1 has been shown to be a direct
target of p53 [33]. Restoration of p53 expression in human cancer
cell lines has been shown to up-regulate the expression of Notch1
[33]. Because PC-3 and DU145 cells, both of which lack
functional p53, behave similarly with regards to PEITC-mediated
activation of Notch1 and Notch2, possibility that differential
Figure 2. Phenethyl isothiocyanate (PEITC) treatment increases transcriptional activity of Notch in malignant and normal prostate
cells. (A) Effect of PEITC treatment on RBP-Jk luciferase reporter activity (a measure of transcriptional activity of Notch) in LNCaP, PC-3, DU145, and
PrEC cells after 8- or 16-hour treatment with dimethyl sulfoxide (DMSO) or 5 mM PEITC. Results shown are mean 6 SD (n=3). *Significantly different
(P,0.05) compared with DMSO-treated control by one-way ANOVA followed by Dunnett’s test (LNCaP and PC-3) or Student’s t-test (DU145 and
PrEC). (B) Immunoblotting for cleaved Notch1 and cleaved Notch2 using lysates from DU145 and PrEC cells treated with DMSO (control) or PEITC (2.5
or 5 mM) for the indicated time periods. Blots were stripped and re-probed with anti-actin antibody. Arrow in panel B (DU145 cells) identifies cleaved
Notch2, the lower band is non-specific based on siRNA results shown in Fig. 4A. Immunoblotting for each protein was done at least twice using
independently prepared lysates. Numbers above bands represent changes in protein levels relative to corresponding DMSO-treated control. Each
experiment was repeated at least twice.
doi:10.1371/journal.pone.0026615.g002
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DU145) is manifested, partially if not completely, by the p53 can’t
be discarded at present. At the same time, we are aware that the
regulation of expression as well as activation of Notch1 is quite
complex mediated by other factors besides p53, including Nrf2,
ETS transcription factor family member PEA3, epidermal growth
factor receptor signaling, and Akt to name a few [34–37]. While
further studies are needed to resolve this question surrounding
p53, it is reasonable to conclude that the differential response
between LNCaP and PC-3 cells is not related to androgen-
responsiveness because LNCaP cells and its androgen-independent
variant LNCaP2C4-2 exhibit generally comparable response to
PEITC-mediated changes in Notch signaling components. In this
context, it is important to mention that Notch target HEY (Hairy/
Figure 3. Phenethyl isothiocyanate (PEITC) increases nuclear levels of cleaved Notch2 protein in LNCaP and PC-3 cells. (A)
Immunofluorescence microscopic images depicting nuclear levels of cleaved Notch2 protein in LNCaP and PC-3 cells after 8-hour treatment with
dimethyl sulfoxide (DMSO) or 5 mM PEITC at 1006objective magnification. Quantitation of Notch1, Notch2, Jagged1, and Jagged2 mRNA levels by
real-time RT-PCR in (B) LNCaP and (C) PC-3 cells after 8-hour treatment with DMSO (control) or PEITC (2.5 or 5 mM). Results shown are mean 6 SD
(n=3). *Significantly different (P,0.05) compared with DMSO-treated control by one-way ANOVA with Dunnett’s adjustment. Each experiment was
repeated at least twice.
doi:10.1371/journal.pone.0026615.g003
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cells. (A) Immunoblotting for cleaved Notch2 protein using lysates from LNCaP and PC-3 cells transiently transfected with a control (non-specific)
siRNA or a Notch2-targeted siRNA and treated for 24 hours with dimethyl sulfoxide (DMSO) or 5 mM PEITC. Numbers above bands represent changes
in protein levels relative to control siRNA-transfected cells treated with DMSO. Arrow (PC-3) identifies cleaved Notch2, the lower band is non-specific.
(B) Histone-associated DNA fragment release into the cytosol (a measure of apoptosis) in LNCaP and PC-3 cells transiently transfected with a control
siRNA or a Notch2-targeted siRNA and treated for 24 hours with DMSO (control) or 5 mM PEITC. Results are expressed as apoptosis enrichment
relative to control siRNA-transfected cells treated with DMSO. (C) Immunoblotting for cleaved Notch1 and cleaved Notch2 proteins using lysates from
LNCaP and PC-3 cells treated for 8 hours or 24 hours with DMSO (control) or 5 mM PEITC in the absence or presence of 50 mM DAPT. Numbers above
bands represent changes in protein levels relative to corresponding DMSO-treated control. (D) Histone-associated apoptotic DNA fragment release
into the cytosol in LNCaP and PC-3 cells treated for 24 hours with DMSO (control) or 5 mM PEITC in the absence or presence of 50 mM DAPT. Results
are expressed as apoptosis enrichment relative to DMSO-treated control. Results (panels B and D) are mean 6 SD (n=3). *Significantly different
(P,0.05) between the indicated groups by one-way ANOVA followed by Bonferroni’s multiple comparison test. Each experiment was repeated twice,
and representative data from one such experiment are shown.
doi:10.1371/journal.pone.0026615.g004
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receptor selective co-repressor [38].
Activation of Notch2 by overexpression of its intracellular
domain promotes apoptosis in MDA-MB-231 cells [26]. It was of
interest to determine the consequences of Notch activation on
proapoptotic response to PEITC in our model. Unlike Notch1
[30], a 40–60% knockdown of Notch2 protein has no meaningful
impact on apoptosis in LNCaP or PC-3 cells. However, apoptosis
resulting from PEITC exposure is significantly attenuated by
Notch2 knockdown at least in PC-3 cells. On the other hand,
suppression of Notch1 activation with DAPT has no effect on
proapoptotic response to PEITC. Based on these results we
conclude that Notch1 is dispensable for cell death resulting from
PEITC exposure in PC-3 and LNCaP cells. Mechanism by which
Notch2 knockdown confers protection against PEITC-induced
apoptosis is not yet clear. Inhibition of several anti-apoptotic
pathways, such as NF-kB and STAT3, coupled with alterations in
expression of Bcl-2 family proteins have been implicated in
apoptosis induction by PEITC [10,11,17,19,39]. It is possible that
Notch2 knockdown alters effect of PEITC on some of these
pathways to confer protection against apoptosis.
Metastasis is the primary cause of mortality from prostate
cancer. Notably, Notch has been implicated in EMT [27], which
promotes metastasis [40]. Moreover, treatment of LNCaP and
PC-3 cells with c-secretase inhibitor DAPT has been shown to
inhibit cell motility [41]. The present study reveals that motility of
both LNCaP and PC-3 cells is reduced significantly by knockdown
of Notch2 protein using siRNA (decreased but not significant in
LNCaP) as well as DAPT-mediated inhibition of Notch1
activation (reduced but not significant in PC-3). Furthermore,
PEITC-mediated inhibition of LNCaP and PC-3 cell migration is
augmented by knockdown of Notch2 protein as well as
pharmacological inhibition of Notch1 cleavage (PC-3 only).
Mechanism by which Notch2 knockdown inhibits cell migration
remains elusive, but this issue has been studied for Notch1 [28].
Targeted depletion of Notch1 inhibits PC-3 and 22Ru1 cell
migration by down-regulating expression of matrix metalloprotei-
nase-9 and urokinase plasminogen activator [28]. It is possible that
Notch2 knockdown elicits similar response on matrix metallopro-
teinase-9 and urokinase plasminogen activator.
In conclusion, the present study demonstrates that PEITC
treatment promotes cleavage of Notch1 and Notch2 leading to
their transcriptional activation in both cancerous (LNCaP, PC-3,
and DU145) and normal (PrEC) prostate cells. PEITC-induced
apoptosis in prostate cancer cells is modestly attenuated by
knockdown of Notch2, but not by pharmacological inhibition of
Notch1 activation. On the other hand, targeted depletion of
Notch2 by siRNA as well as inhibition of Notch1 activation using
DAPT augments prostate cancer cell motility inhibition by
PEITC.
Figure 5. RNA interference of Notch2 augments phenethyl isothiocyanate (PEITC)-mediated inhibition of LNCaP and PC-3 cell
migration. Representative images (Boyden chamber assay) depicting migration of (A) LNCaP and (C) PC-3 cells transfected with a control (non-
specific) siRNA or a Notch2-targeted siRNA and treated for 24 hours with dimethyl sulfoxide (DMSO) or 5 mM PEITC at 2006 magnification.
Quantitation of migrated (B) LNCaP cells and (D) PC-3 cells from experiments shown in panels A and C. Three to four fields on each filter were scored
for migrated cells under an inverted microscope at 2006 magnification. Results shown are mean 6 SD (n=3). *Significantly different (P,0.05)
between the indicated groups by one-way ANOVA followed by Bonferroni’s multiple comparison test. Each experiment was repeated twice, and
representative data from one such experiment are shown.
doi:10.1371/journal.pone.0026615.g005
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Ethics statement
We used archived tissue sections from our previously published
in vivo studies [6,13,16] to determine the effect of PEITC
administration on expression of cleaved Notch2. Use of mice
and their care for these studies [6,13,16] was approved by and in
accordance with the University of Pittsburgh Institutional Animal
Care and Use Committee guidelines.
Reagents
PEITC (purity .98%) was purchased from LKT Laboratories
(St. Paul, MN). Cell culture reagents were purchased from
Invitrogen-Life Technologies (Carlsbad, CA). Antibodies used in
the present study were purchased from the following sources:
antibodies against cleaved Notch1, Presenilin1, Jagged1, Jagged2,
and Nicastrin were from Cell Signaling Technology (Danvers,
MA); an antibody specific for detection of cleaved Notch2 was
from EMD-Millipore (Billerica, MA); and anti-actin antibody was
from Sigma-Aldrich (St. Louis, MO). A c-secretase inhibitor
(DAPT) was purchased from Calbiochem (Billerica, MA). Notch2-
targeted siRNA was purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). A non-specific control siRNA was purchased
from Qiagen (Germantown, MD).
Cell lines
LNCaP, PC-3, and DU145 human prostate cancer cell lines
were obtained from American Type Culture Collection (Manassas,
VA), and maintained as described by us previously [10,13,42,43].
PrEC cells were purchased from Clonetics (SanDiego, CA) and
maintained as described by us previously [11]. Cell line
authentication was done by Research Animal Diagnostic Labora-
tory (University of Missouri, Columbia, MO). The cells were last
tested in February 2011 and found to be of human origin.
Moreover, genetic profile for each cell line was consistent with
those in the American Type Culture Collection database.
LNCaP2C4-2 cell line (not authenticated by us) was obtained
from UroCor and maintained as described by us previously [43].
Immunoblotting
Stock solution of PEITC was prepared in DMSO and an equal
volume of DMSO (final concentration 0.1%) was added to
Figure 6. Phenethyl isothiocyanate (PEITC)-mediated inhibition of prostate cancer cell migration is augmented by a c-secretase
inhibitor. Representative images (Boyden chamber assay) depicting migration of (A) LNCaP and (C) PC-3 cells after 24-hour treatment with dimethyl
sulfoxide (DMSO) or 5 mM PEITC in the absence or presence of 50 mM DAPT at 2006magnification. Quantitation of migrated (B) LNCaP cells and (D)
PC-3 cells after 24-hour treatment with DMSO or 5 mM PEITC and/or 50 mM DAPT. Three to four fields on each filter were scored for migrated cells
under an inverted microscope. Results shown are mean 6 SD (n=3). *Significantly different (P,0.05) between the indicated groups by one-way
ANOVA followed by Bonferroni’s multiple comparison test. Each experiment was repeated twice, and representative data from one such experiment
are shown.
doi:10.1371/journal.pone.0026615.g006
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collected and processed for immunoblotting as described by us
previously [6,44].
Luciferase reporter assay
Cignal RBP-Jk luciferase reporter kit from SABiosciences-
Qiagen was used to determine the effect of PEITC treatment on
transcriptional activity of Notch. The RBP-Jk [C protein binding
factor 1/Suppressor of Hairless/Lag1 (CBF1/Su (H)/Lag 1)] is a
direct downstream modulator of Notch signaling [23,24]. Notch
intracellular domain (cleaved Notch) binds to CSL/CBF1/Su (H)/
Lag 1 and converts it from a transcriptional repressor to a
transcriptional activator [23,24]. Desired cells were transfected
with the reporter construct using Fugene6. Twenty-four hours
after transfection, cells were treated with DMSO (control) or
PEITC (5 mM) for 8 or 16 hours, and harvested using lysis buffer.
Samples were centrifuged, and 20 mL aliquot was used for
measurement of dual luciferase activity using a luminometer.
Luciferase activity was normalized to protein concentration and
expressed as a ratio of firefly luciferase to renilla luciferase units.
Figure 7. In vivo effect of phenethyl isothiocyanate on expression of cleaved Notch2 protein in prostate tumor. (A) Representative H&E
staining and immunohistochemical staining for expression of cleaved Notch2 protein in PC-3 xenografts from three mice of the indicated groups
(scale bar, 50 mm; magnification, 4006). Amplification of selected area is shown in the inset. Quantitation of nuclear expression of Notch2 protein in
PC-3 xenografts from control and phenethyl isothiocyanate (PEITC)-treated mice is shown in the bar graph (mean 6 SD; n=3). (B)
Immunohistochemistry showing cleaved Notch2 protein expression in the dorsolateral prostates from four TRAMP mice of the indicated groups
(scale bar, 50 mm; magnification, 4006). Amplification of selected area is shown in the inset. Quantitation of nuclear expression of cleaved Notch2
protein in the dorsolateral prostates of control and PEITC-fed TRAMP mice is shown in the bar graph (mean 6 SD; n=4). Statistical significance was
determined by Student’s t-test.
doi:10.1371/journal.pone.0026615.g007
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LNCaP or PC-3 cells (1610
5) were grown on coverslips in 12-
well plates and allowed to attach by overnight incubation. Cells
were treated with DMSO (control) or PEITC (5 mM) for 8 hours,
fixed with 2% paraformaldehyde for 1 hour at room temperature,
and permeabilized using 0.5% Triton X-100 for 5 minutes. Cells
were then incubated with phosphate-buffered saline (PBS)
supplemented with 0.5% bovine serum albumin and 0.15%
glycine for 1 hour followed by overnight incubation with anti-
cleaved Notch2 antibody (1:500 dilution in above buffer) at 4uC.
Next day, cells were treated with 2 mg/mL of Alexa Fluor-488-
conjugated secondary antibody for 1 hour at room temperature.
After washing with PBS, cells were treated with 50 ng/mL 49,6-
diamidino-2-phenylindole (DAPI) for 5 minutes at room temper-
ature to stain nuclear DNA. Cells were mounted and visualized
under a fluorescence microscope.
Real-time reverse transcription-PCR (RT-PCR)
Total RNA from DMSO-treated control and PEITC-treated
cells was isolated using RNeasy kit (Qiagen). First-strand cDNA
was synthesized using Superscript reverse transcriptase (Invitro-
gen-Life Technologies) with oligo (dT)20 primer. Primers were as
follows: Notch1: forward 59-CACTGTGGGCGGGTCC-39, re-
verse 59-GTTGTATTGGTTCGGCACCAT-39; Notch2: forward
59-AATCCCTGACTCCAGAACG-39, reverse 59-TGGTAGAC-
CAAGTCTGTGATGAT-39; Jagged1: forward 59-CTATGAT-
GAGGGGGATGCT-39, reverse 59-CGTCCATTCAGGCAC-
TGG-39; Jagged2: forward 59-TGGGATGCCTGGCACA-39,
reverse 59-CCGGCAGATGCAGGA-39; GAPDH: forward 59-
GGACCTGACCTGCCGTCTAGAA-39, reverse 59-GGTGTC-
GCTGTTGAAGTCAGAG-39. Quantitative real-time RT-PCR
was done using 26SYBR Green master mix (Applied Biosystems-
Life Technologies) with 55uC annealing (45 seconds for Notch1 and
Notch2), 53uC annealing (45 seconds for Jagged1 and Jagged2) for 40
cycles. Relative gene expression was calculated using the method
described by Livak and Schmittgen and normalized against
GAPDH [45].
RNA interference of Notch2
LNCaP or PC-3 cells were transfected at ,50% confluency
with 100 nmol/L of Notch2- targeted siRNA or control siRNA
using Oligofectamine. Twenty-four hours after transfection, cells
were treated with DMSO (control) or PEITC (5 mM) for 24 hours.
Subsequently, cells were collected and processed for western
blotting, quantitation of histone-associated DNA fragment release
into the cytosol (a method for quantitation of apoptosis), and cell
migration. Histone-associated DNA fragment release into the
cytosol was quantified using Cell Death Detection ELISA kit
(Roche Applied Science, Indianapolis, IN) by following the
manufacturer’s instructions.
Cell migration assay
Transwell Boyden chambers containing 8.0 mm pore size
polycarbonate filter (Corning-Life Sciences, Big Flats, NY) were
used to determine cell migration. LNCaP or PC-3 cells were
transfected with a control siRNA or Notch2-targeted siRNA as
above, and used for cell migration assay described by us previously
[20].
Immunohistochemistry
Immunohistochemistry was performed essentially as described
by us previously for other proteins [6,16]. Three (xenografts) or
five dorsolateral prostate specimens (TRAMP tissues) from
different mice of each group were used. Data for one TRAMP
mouse from both groups was not included in the analysis due to
larger than usual variation. Multiple non-overlapping representa-
tive images from each section were captured using Image ProPlus
5.0 software. Expression of cleaved Notch2 in the nucleus was
determined using Nuclear v9.1 algorithm of Aperio Image Scope
software. This software automatically counts stained (brown color)
nuclei and categorizes them according to intensity (0, 1+,2 + or
3+). Results are computed as percent positive nuclei accounting for
both nuclear count and intensity.
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